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Steven Finkbeiner, 1, 2 Bianxiao Cui, 3 Lennart Mucke 1,2 * A myloid-b (Ab) peptides, derived from the amyloid precursor protein (APP), and the microtubule-associated protein tau are key pathogenic factors in Alzheimer's disease (AD). However, the exact mechanisms by which they impair cognitive functions are unknown. Human APP (hAPP) transgenic mice have high Ab concentrations in the brain and develop aberrant neuronal activity and behavioral deficits (1, 2) . Lowering endogenous tau prevents these abnormalities without affecting baseline neuronal functions (1, 2) . The mechanisms of this rescue are unknown. Axonal transport is critical for neuronal function and is impaired by Ab (3-6). Whether tau also affects axonal transport is controversial (7) (8) (9) .
To explore whether tau reduction prevents Ab-induced defects in axonal transport, we studied axonal transport of mitochondria and the neurotrophin receptor TrkA, whose neuronal distributions are altered in AD (10, 11) . Hippocampal neuronal cultures from tau-deficient (Tau ) controls were transfected with plasmids expressing fluorescent markers of mitochondria [mito-red fluorescent protein (RFP)] or TrkA (TrkA-mCherry). At 10 to 14 days in vitro, cargo motility (moving cargoes/ total cargoes) and velocity (mm/s) were assessed before and after treatment with Ab 1-42 oligomers (2 mM) (12) . Ab rapidly inhibited axonal motility of mitochondria and TrkA in wild-type neurons. The effect was stronger on anterograde (mitochondria, P < 0.001; TrkA, P < 0.001) than retrograde (mitochondria, P < 0.01; TrkA, nonsignificant) transport. Complete or partial tau reduction prevented these defects without affecting axonal transport at baseline ( Fig. 1 and movies S1 to S6). Moving cargoes had similar velocities in all Tau genotypes at baseline and after Ab treatment.
Tau reduction did not enhance axonal transport under physiological conditions. However, tau levels were more critical for axonal transport in the presence of Ab. Ab oligomers impair axonal motility of cargoes through complex mechanisms involving N-methyl-D-aspartate receptor signaling (3), activation of glycogen synthase kinase 3b (3, 4) and casein kinase 2 (5), and actin polymerization (6) . Why Ab requires tau to impair axonal transport is uncertain; tau might interact directly or indirectly with any of these pathways or enhance the effects independently by competing with motor proteins for microtubule access (7) . Although most concentrated in axons, tau may have Ab-enabling activities also in dendrites (2) .
Tau ablation induces axonal spheroids in Tg2576 APP transgenic mice (13) , but the functional importance is unknown. Tau reduction prevents Abinduced neuronal and behavioral deficits in hAPPJ20 mice (1) and APP23 mice (2) . Protection against Ab-induced defects in axonal transport is one of several possible mechanisms for this rescue.
Although tau did not affect axonal transport under baseline untreated conditions in vitro (this study) or in vivo (9) , it may still be important under physiologic conditions. For example, local tau gradients may promote cargo detachment at strategic points (7, 13) . Tau may also regulate cellular transport of its binding partners (2) , and tau reduction might have affected axonal transport of cargoes we did not assess. Partial tau reduction may strike a balance between therapeutic safety and efficacy because it prevented Ab-induced axonal transport defects as well as aberrant neuronal activity (1), cognitive deficits (1), and premature mortality (1, 2) in hAPP mice. In addition to tau reduction strategies, components of the axonal transport machinery and of Ab-or tau-related signaling cascades are potential therapeutic targets warranting further investigation.
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Abstract
Amyloid-b (Ab) peptides, derived from the amyloid precursor protein, and the microtubule-associated protein tau are key pathogenic factors in Alzheimer's disease (AD). How exactly they impair cognitive functions is unknown. We assessed the effects of Ab and tau on axonal transport of mitochondria and the neurotrophin receptor TrkA, cargoes that are critical for neuronal function and survival and whose distributions are altered in AD. Ab oligomers rapidly inhibited axonal transport of these cargoes in wild-type neurons. Lowering tau levels prevented these defects without affecting baseline axonal transport. Thus, Ab requires tau to impair axonal transport, and tau reduction protects against Ab-induced axonal transport defects.
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